Fennec Pharmaceuticals Inc. has released a corporate presentation highlighting its progress with PEDMARK®, the first and only FDA-approved therapy for cisplatin-induced ototoxicity $(CIO)$. PEDMARK® is endorsed in NCCN treatment guidelines for preventing CIO in adolescent and young adult cancer patients. The company emphasizes its robust intellectual property portfolio, including orphan drug exclusivity and pediatric use marketing authorization, supporting long-term differentiation and global expansion. Fennec notes ongoing partnerships in Europe, preparations for registration in Japan, and expansion efforts in the GCC market. The presentation also addresses the impact of cisplatin-induced hearing loss on cancer survivors and underscores the need for therapies that protect auditory health during treatment. You can access the full presentation through the link below.